From May 29 to June 1, 2024, the 70th Annual Meeting of the American Society for Artificial Internal Organs (ASAIO) was held in Baltimore, Maryland, USA. CH Biomedical was the only VAD company form China invited to participate, where it showcased its latest R&D achievements and breakthrough innovations, drawing significant attention from the international VAD community.
At the conference, Dr. Gill Bearnson, Vice President of Systems Engineering at CH Biomedical USA, delivered a keynote speech on Pediatric Device Day. He introduced BrioVAD, the Company's latest fully magnetically levitated left ventricular assist system (LVAS), independently developed by CH Biomedical. Building on the excellent hemocompatibility of the CH-VAD, BrioVAD incorporates multiple technological innovations to enhance the portability of external components and significantly improve system’s overall performance. Dr. Bearnson highlighted the compact design of the BrioVAD pump—identical in size to the CH-VAD pump but substantially thinner than other products in the same category globally—demonstrating its superior size advantages. He also shared updates on its clinical applications in patients with small body surface areas, underlining the system’s future potential for pediatric applications.
Dr. Gill Bearnson Delivered a Keynote Speech at the Conference
BrioVAD has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA), becoming the first original Chinese-developed active implantable medical device to enter FDA-approved clinical trials. The product is scheduled to initiate the INNOVATE Trial later this year, a breakthrough that drew significant attention from global experts at the meeting. The INNOVATE study will utilize a randomized controlled trial (RCT) design to compare BrioVAD with the previously FDA-approved device, offering clinicians and patients with advanced heart failure expanded treatment options.
O.H. Frazier (left), a global pioneer in ventricular assist devices (VAD) and recipient of the ASAIO Lifetime Achievement Award
BrioVAD system Draws Global Expert Attention at ASAIO 2024
ASAIO is a globally respected academic society founded for educational and scientific purposes. It is committed to advancing the development, application, and awareness of artificial organ technologies to improve human health and longevity. The Society brings together individuals and groups organizations focused on the progress of artificial internal organs. Its annual meeting serves as a a premier global platform for interdisciplinary exchange, attracting leading clinicians, scientists, and engineers to collaborate on next-generation medical technologies. CH Biomedical has been continuously invited to this prestigious conference for over a decade, regularly presenting the latest product innovations—demonstrating the company's sustained innovation and growing recognition on the international stage.
Looking ahead, CH Biomedical will continue to drive innovation in VAD technology and foster global academic exchange in the field. By advancing cutting-edge solutions, the Company aims to make innovative therapies more accessible to patients with advanced heart failure worldwide.
